HIV and aging

International Journal of Infectious Diseases

Volumn 53, Issue , 2016, Pages 61-68

  Wing, Edward J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Aging; Antiretroviral; Co morbidities; HIV; Inflammation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGING; ANTIRETROVIRAL THERAPY; BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; COMORBIDITY; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; FRACTURE; FRAILTY; GERIATRIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DYSREGULATION; INFECTION PREVENTION; INFECTION RISK; KIDNEY DISEASE; LIFE EXPECTANCY; LIFESPAN; MALIGNANT NEOPLASM; MEDICAL HISTORY; METABOLIC SYNDROME X; MORTALITY RATE; NEUROLOGICAL COMPLICATION; OSTEOPOROSIS; PATIENT CARE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCREENING TEST; TERMINAL CARE; VIRUS ACTIVATION; CD4 LYMPHOCYTE COUNT; DISEASE MANAGEMENT; GERIATRICS; HIV INFECTIONS; INFLAMMATION; POLYPHARMACY; VIRUS LOAD;

AGING; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DISEASE MANAGEMENT; GERIATRICS; HIV INFECTIONS; HUMANS; INFLAMMATION; LIFE EXPECTANCY; POLYPHARMACY; QUALITY OF LIFE; VIRAL LOAD;

EID: 85001103516     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.10.004     Document Type: Review

References (107)

1. 1 HIV and aging: a special supplement to the UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2013.
2. 2 Centers for Disease Control and Prevention. HIV surveillance report, 25, 2013 Published February 2015.
3. 3 O'Keefe, K.J., Scheer, S., Chen, M.J., Hughes, A.J., Pipkin, S., People fifty years or older now account for the majority of AIDS cases in San Francisco, California, 2010. AIDS Care 25 (2013), 1145–1148.
4. 4 Mary-Krause, M., Grabar, S., Lievre, L., Abgrall, S., Billaud, E., Boue, F., et al. Cohort profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol 43 (2014), 1425–1436.
5. 5 Weber, R., Ruppik, M., Rickenbach, M., Spoerri, A., Furrer, H., Battegay, M., et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 14 (2013), 195–207.
6. 6 Rodger, A.J., Lodwick, R., Schechter, M., Deeks, S., Amin, J., Gilson, R., et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 27 (2013), 973–979.
7. 7 Antiretroviral Therapy Cohort C, Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372 (2008), 293–299.
8. 8 Lewden, C., Chene, G., Morlat, P., Raffi, F., Dupon, M., Dellamonica, P., et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 46 (2007), 72–77.
9. 9 Legarth, R.A., Ahlstrom, M.G., Kronborg, G., Larsen, C.S., Pedersen, C., Pedersen, G., et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr 71 (2016), 213–218.
10. 3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 41 (2012), 433–445.
11. 11 Samji, H., Cescon, A., Hogg, R.S., Modur, S.P., Althoff, K.N., Buchacz, K., et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One, 8, 2013, e81355.
12. 12 Lohse, N., Hansen, A.B., Pedersen, G., Kronborg, G., Gerstoft, J., Sorensen, H.T., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146 (2007), 87–95.
13. 13 Losina, E., Schackman, B.R., Sadownik, S.N., Gebo, K.A., Walensky, R.P., Chiosi, J.J., et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49 (2009), 1570–1578.
14. 14 Sabin, C.A., Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?. BMC Med, 11, 2013, 251.
15. 15 May, M., Gompels, M., Delpech, V., Porter, K., Post, F., Johnson, M., et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ, 343, 2011, d6016.
16. 16 May, M.T., Gompels, M., Delpech, V., Porter, K., Orkin, C., Kegg, S., et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 28 (2014), 1193–1202.
17. 17 Wong, C., Althoff, K., Gange, S.J., Identifying the appropriate comparison group for HIV-infected individuals. Curr Opin HIV AIDS 9 (2014), 379–385.
18. 18 Marcus, J.L., Chao, C.R., Leyden, W.A., Xu, L., Quesenberry, C.P. Jr., Klein, D.B., et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 73 (2016), 39–46.
19. 19 The Antiretroviral Therapy Cohort Collaboration, Gill, J., May, M., et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50 (2010), 1387–1396.
20. 20 French, A.L., Gawel, S.H., Hershow, R., Benning, L., Hessol, N.A., Levine, A.M., et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 51 (2009), 399–406.
21. 21 Lewden, C., Salmon, D., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34 (2005), 121–130.
22. 22 Morlat, P., Roussillon, C., Henard, S., Salmon, D., Bonnet, F., Cacoub, P., et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 28 (2014), 1181–1191.
23. 23 Smith, C.J., Ryom, L., Weber, R., Morlat, P., Pradier, C., Reiss, P., et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384 (2014), 241–248.
24. 24 Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
25. 25 Horvath, S., Levine, A.J., HIV-1 infection accelerates age according to the epigenetic clock. J Infect Dis 212 (2015), 1563–1573.
26. 26 Nordell, A.D., McKenna, M., Borges, A.H., Duprez, D., Neuhaus, J., Neaton, J.D., et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc, 3, 2014, e000844.
27. 27 Borges, A.H., O'Connor, J.L., Phillips, A.N., Ronsholt, F.F., Pett, S., Vjecha, M.J., et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis 212 (2015), 585–595.
28. 28 Nixon, D.E., Landay, A.L., Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 5 (2010), 498–503.
29. 29 So-Armah, K.A., Tate, J.P., Chang, C.C., Butt, A.A., Gerschenson, M., Gibert, C.L., et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people?. J Acquir Immune Defic Syndr 72 (2016), 206–213.
30. 30 Kamat, A., Misra, V., Cassol, E., Ancuta, P., Yan, Z., Li, C., et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One, 7, 2012, e30881.
31. 31 Freiberg, M.S., Bebu, I., Tracy, R., So-Armah, K., Okulicz, J., Ganesan, A., et al. D-dimer levels before HIV seroconversion remain elevated even after viral suppression and are associated with an increased risk of non-AIDS events. PLoS One, 11, 2016, e0152588.
32. 32 Dampier, W., Nonnemacher, M.R., Mell, J., Earl, J., Ehrlich, G.D., Pirrone, V., et al. HIV-1 genetic variation resulting in the development of new quasispecies continues to be encountered in the peripheral blood of well-suppressed patients. PLoS One, 11, 2016, e0155382.
33. 33 Lorenzo-Redondo, R., Fryer, H.R., Bedford, T., Kim, E.Y., Archer, J., Kosakovsky Pond, S.L., et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530 (2016), 51–56.
34. 34 Martinez-Picado, J., Deeks, S.G., Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS 11 (2016), 417–423.
35. 35 Naeger, D.M., Martin, J.N., Sinclair, E., Hunt, P.W., Bangsberg, D.R., Hecht, F., et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One, 5, 2010, e8886.
36. 36 Dinh, D.M., Volpe, G.E., Duffalo, C., Bhalchandra, S., Tai, A.K., Kane, A.V., et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis 211 (2015), 19–27.
37. 37 Angelovich, T.A., Hearps, A.C., Maisa, A., Martin, G.E., Lichtfuss, G.F., Cheng, W.J., et al. Viremic and virologically suppressed HIV infection increases age-related changes to monocyte activation equivalent to 12 and 4 years of aging, respectively. J Acquir Immune Defic Syndr 69 (2015), 11–17.
38. 38 Pathai, S., Bajillan, H., Landay, A.L., High, K.P., Is HIV a model of accelerated or accentuated aging?. J Gerontol A Biol Sci Med Sci 69 (2014), 833–842.
39. 39 Justice, A., Falutz, J., Aging and HIV: an evolving understanding. Curr Opin HIV AIDS 9 (2014), 291–293.
40. 40 Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908 (2000), 244–254.
41. 41 Althoff, K.N., McGinnis, K.A., Wyatt, C.M., et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 60 (2015), 627–638.
42. 42 Rasmussen, L.D., May, M.T., Kronborg, G., et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV 2 (2015), e288–e298.
43. 43 Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., Sighem, A., et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 15 (2015), 810–818.
44. 44 Barbaro, G., Di Lorenzo, G., Grisorio, B., Barbarini, G., Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 339 (1998), 1093–1099.
45. 45 Thiara, D.K., Liu, C.Y., Raman, F., Mangat, S., Purdy, J.B., Duarte, H.A., et al. Abnormal myocardial function is related to myocardial steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis 212 (2015), 1544–1551.
46. 46 Feinstein, M.J., Bahiru, E., Achenbach, C., Longenecker, C.T., Hsue, P., So-Armah, K., et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol 117 (2016), 214–220.
47. 47 Martin-Iguacel, R., Llibre, J.M., Friis-Moller, N., Risk of cardiovascular disease in an aging HIV population: where are we now?. Curr HIV/AIDS Rep 12 (2015), 375–387.
48. 48 Freiberg, M.S., Chang, C.C., Kuller, L.H., Skanderson, M., Lowy, E., Kraemer, K.L., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173 (2013), 614–622.
49. 49 Sico, J.J., Chang, C.C., So-Armah, K., Justice, A.C., Hylek, E., Skanderson, M., et al. HIV status and the risk of ischemic stroke among men. Neurology 84 (2015), 1933–1940.
50. 50 Obel, N., Thomsen, H.F., Kronborg, G., Larsen, C.S., Hildebrandt, P.R., Sorensen, H.T., et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 44 (2007), 1625–1631.
51. 51 Klein, D.B., Leyden, W.A., Xu, L., Chao, C.R., Horberg, M.A., Towner, W.J., et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis 60 (2015), 1278–1280.
52. 52 Kooij, K.W., Wit, F.W., Bisschop, P.H., Schouten, J., Stolte, I.G., Prins, M., et al. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis 211 (2015), 539–548.
53. 53 Walker Harris, V., Brown, T.T., Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis, 205(Suppl 3), 2012 S391–8.
54. 54 Prieto-Alhambra, D., Guerri-Fernandez, R., De Vries, F., Lalmohamed, A., Bazelier, M., Starup-Linde, J., et al. HIV infection and its association with an excess risk of clinical fractures: a nationwide case–control study. J Acquir Immune Defic Syndr 66 (2014), 90–95.
55. 55 Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
56. 56 Jarrett, O.D., Wanke, C.A., Ruthazer, R., Bica, I., Isaac, R., Knox, T.A., Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDs 27 (2013), 266–271.
57. 57 Ford, E.S., Li, C., Zhao, G., Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2 (2010), 180–193.
58. 58 Monroe, A.K., Glesby, M.J., Brown, T.T., Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis 60 (2015), 453–462.
59. 59 Rasmussen, L.D., Mathiesen, E.R., Kronborg, G., Pedersen, C., Gerstoft, J., Obel, N., Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. PLoS One, 7, 2012, e44575.
60. 60 Mallipattu, S.K., Salem, F., Wyatt, C.M., The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. Kidney Int 86 (2014), 259–265.
61. 61 Ando, M., Tsuchiya, K., Nitta, K., How to manage HIV-infected patients with chronic kidney disease in the HAART era. Clin Exp Nephrol 16 (2012), 363–372.
62. 62 Abraham, A.G., Althoff, K.N., Jing, Y., Estrella, M.M., Kitahata, M.M., Wester, C.W., et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis 60 (2015), 941–949.
63. 63 d'Arminio Monforte, A., Duca, P.G., Vago, L., Grassi, M.P., Moroni, M., Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 54 (2000), 1856–1859.
64. 64 Heaton, R.K., Clifford, D.B., Franklin, D.R. Jr., Woods, S.P., Ake, C., Vaida, F., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75 (2010), 2087–2096.
65. 65 Valcour, V., Shikuma, C., Shiramizu, B., Watters, M., Poff, P., Selnes, O., et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63 (2004), 822–827.
66. 66 Becker, J.T., Maruca, V., Kingsley, L.A., Sanders, J.M., Alger, J.R., Barker, P.B., et al. Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology 54 (2012), 113–121.
67. 67 Heaton, R.K., Franklin, D.R. Jr., Deutsch, R., Letendre, S., Ellis, R.J., Casaletto, K., et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60 (2015), 473–480.
68. 68 Schuster, R.M., Gonzalez, R., Substance abuse, hepatitis C, and aging in HIV: common cofactors that contribute to neurobehavioral disturbances. Neurobehav HIV Med 2012, 2012, 15–34.
69. 69 Cysique, L.A., Franklin, D. Jr., Abramson, I., Ellis, R.J., Letendre, S., Collier, A., et al. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 33 (2011), 505–522.
70. 70 Mothobi, N.Z., Brew, B.J., Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis 25 (2012), 4–9.
71. 71 Weber, E., Blackstone, K., Woods, S.P., Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev 23 (2013), 81–98.
72. 72 Patel, P., Hanson, D.L., Sullivan, P.S., Novak, R.M., Moorman, A.C., Tong, T.C., et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148 (2008), 728–736.
73. 73 Franceschi, S., Lise, M., Clifford, G.M., Rickenbach, M., Levi, F., Maspoli, M., et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 103 (2010), 416–422.
74. 74 Simard, E.P., Pfeiffer, R.M., Engels, E.A., Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117 (2011), 1089–1096.
75. 75 Park, L.S., Tate, J.P., Sigel, K., Rimland, D., Crothers, K., Gibert, C., et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. AIDS 30 (2016), 1795–1806.
76. 76 Silverberg, M.J., Lau, B., Achenbach, C.J., Jing, Y., Althoff, K.N., D'Souza, G., et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163 (2015), 507–518.
77. 77 Yanik, E.L., Katki, H.A., Engels, E.A., Cancer risk among the HIV-infected elderly in the United States. AIDS 30 (2016), 1663–1668.
78. 78 Shepherd, L., Borges, A., Ledergerber, B., Domingo, P., Castagna, A., Rockstroh, J., et al. Infection-related and -unrelated malignancies, HIV and the aging population. HIV Med 17 (2016), 590–600.
79. 79 Coghill, A.E., Shiels, M.S., Suneja, G., Engels, E.A., Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33 (2015), 2376–2383.
80. 80 Masten, J., A shrinking kind of life”: gay men's experience of aging with HIV. J Gerontol Soc Work 58 (2015), 319–337.
81. 81 Moore, R.C., Moore, D.J., Thompson, W.K., Vahia, I.V., Grant, I., Jeste, D.V., A case-controlled study of successful aging in older HIV-infected adults. J Clin Psychiatry 74 (2013), e417–e423.
82. 82 Fang, X., Vincent, W., Calabrese, S.K., Heckman, T.G., Sikkema, K.J., Humphries, D.L., et al. Resilience, stress, and life quality in older adults living with HIV/AIDS. Aging Ment Health 19 (2015), 1015–1021.
83. 83 Inouye, S.K., Studenski, S., Tinetti, M.E., Kuchel, G.A., Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55 (2007), 780–791.
84. 84 Greene, M., Covinsky, K.E., Valcour, V., Miao, Y., Madamba, J., Lampiris, H., et al. Geriatric syndromes in older HIV-infected adults. J Acquir Immune Defic Syndr 69 (2015), 161–167.
85. 85 Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56 (2001), M146–M156.
86. 86 Brothers, T.D., Kirkland, S., Guaraldi, G., Falutz, J., Theou, O., Johnston, B.L., et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 210 (2014), 1170–1179.
87. 87 Levett, T.J., Cresswell, F.V., Malik, M.A., Fisher, M., Wright, J., Systematic review of prevalence and predictors of frailty in individuals with human immunodeficiency virus. J Am Geriatr Soc 64 (2016), 1006–1014.
88. 88 Desquilbet, L., Jacobson, L.P., Fried, L.P., Phair, J.P., Jamieson, B.D., Holloway, M., et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 62 (2007), 1279–1286.
89. 89 Pahor, M., Guralnik, J.M., Ambrosius, W.T., Blair, S., Bonds, D.E., Church, T.S., et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA 311 (2014), 2387–2396.
90. 90 Work Group for HIV, Aging Consensus Project, Abrass, C.K., Appelbaum, J.S., et al. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc 60 (2012), 974–979.
91. 91 Greene, M., Justice, A.C., Lampiris, H.W., Valcour, V., Management of human immunodeficiency virus infection in advanced age. JAMA 309 (2013), 1397–1405.
92. 92 Aberg, J.A., Gallant, J.E., Ghanem, K.G., Emmanuel, P., Zingman, B.S., Horberg, M.A., et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis, 58, 2014 e1–34.
93. 93 Edwards, J.K., Cole, S.R., Westreich, D., Mugavero, M.J., Eron, J.J., Moore, R.D., et al. Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States. Clin Infect Dis 61 (2015), 1189–1195.
94. 94 Mills, A., Arribas, J.R., Andrade-Villanueva, J., DiPerri, G., Van Lunzen, J., Koenig, E., et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16 (2016), 43–52.
95. 95 Althoff, K.N., Justice, A.C., Gange, S.J., Deeks, S.G., Saag, M.S., Silverberg, M.J., et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 24 (2010), 2469–2479.
96. 96 Grabar, S., Kousignian, I., Sobel, A., Le Bras, P., Gasnault, J., Enel, P., et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 18 (2004), 2029–2038.
97. 97 Burgess, M.J., Zeuli, J.D., Kasten, M.J., Management of HIV/AIDS in older patients—drug/drug interactions and adherence to antiretroviral therapy. HIV AIDS (Auckl) 7 (2015), 251–264.
98. 98 Ghidei, L., Simone, M.J., Salow, M.J., Zimmerman, K.M., Paquin, A.M., Skarf, L.M., et al. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging 30 (2013), 809–819.
99. 99 Abara, W.E., Adekeye, O.A., Xu, J., Heiman, H.J., Rust, G., Correlates of combination antiretroviral adherence among recently diagnosed older HIV-infected adults between 50 and 64 years. AIDS Behav 20 (2016), 2674–2681.
100. 100 Kariuki, W., Manuel, J.I., Kariuki, N., Tuchman, E., O'Neal, J., Lalanne, G.A., HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl) 8 (2016), 17–36.
101. 101 Edelman, E.J., Tetrault, J.M., Fiellin, D.A., Substance use in older HIV-infected patients. Curr Opin HIV AIDS 9 (2014), 317–324.
102. 102 Shah, K.N., Majeed, Z., Yoruk, Y.B., Yang, H., Hilton, T.N., McMahon, J.M., et al. Enhancing physical function in HIV-infected older adults: a randomized controlled clinical trial. Health Psychol 35 (2016), 563–573.
103. 103 Feeney, E.R., Chung, R.T., Yazdanpanah, Y., Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS 10 (2015), 323–329.
104. 104 Brown, T.T., Hoy, J., Borderi, M., Guaraldi, G., Renjifo, B., Vescini, F., et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 60 (2015), 1242–1251.
105. 105 Overton, E.T., Chan, E.S., Brown, T.T., Tebas, P., McComsey, G.A., Melbourne, K.M., et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med 162 (2015), 815–824.
106. 106 Pinquart, M., Duberstein, P.R., Lyness, J.M., Effects of psychotherapy and other behavioral interventions on clinically depressed older adults: a meta-analysis. Aging Ment Health 11 (2007), 645–657.
107. 107 Brouillette, M.J., Mayo, N., Fellows, L.K., Lebedeva, E., Higgins, J., Overton, E.T., et al. A better screening tool for HIV-associated neurocognitive disorders: is it what clinicians need?. AIDS 29 (2015), 895–902.